[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485269":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":58,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":73,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":82,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Breast cancer",null,"Patients with breast cancer who present for initial cardio-oncology consultation. Clinical follow up for 18 months.",[13],"Other: anonymized data collection during programmed surveillance clinical follow up",{"label":15,"type":10,"description":16,"interventionNames":17},"Hematological malignancies","Patients with lymphomas, leukemias, multiple myeloma, and AL amyloidosis who present for initial cardio-oncology consultation. Clinical follow up for 18 months.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Immune check point inhibitors","Patients with any type of cancer treated with immune check point inhibitors who present for initial cardio-oncology consultation. Clinical follow for 18 months",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"anonymized data collection during programmed surveillance clinical follow up","anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Diego Sadler, MD FACC","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","5613898833","sadlerd@ccf.org",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Rohit Moudgil, MD PhD","216-445-1932","moudgir@ccf.org",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Cleveland Clinic Florida","RECRUITING","Weston","Florida","33331","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-80.39977,26.10037,{"lat":53,"lon":52},[56],{"name":29,"role":33,"phone":57,"phoneExt":10,"email":35},"561-389-8833",{"type":30,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Sadler,Diego MD","MD FACC Associate Professor of Medicine. CCLCM CWRU","100485269","global-cardio-oncology-registry-100485269",false,"NCT05598879","Global Cardio Oncology Registry","G-COR","Inclusion Criteria:\n\n* New cardio-oncology consultation for breast cancer patients, or\n* New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or\n* New cardio-oncology consultation for acute or chronic leukemia patients, or\n* New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or\n* New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.\n* All patients have to be 18 years old or older\n\nExclusion Criteria:\n\n* Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.\n* Minors less than 18 years old.\n* Inability or unwillingness to consent to participate","ALL","18 Years",{"count":71,"type":72},5000,"ESTIMATED","24 Months","OBSERVATIONAL","G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.",[77,78,79,80,81],"Breast Cancer","Hematologic Malignancy","Immune Checkpoint Inhibitor-Related Myocarditis","Cardiotoxicity","Cardiovascular Diseases",[83,84,85,86,87,88,89,90],"cardiotoxicity","Cancer related cardiovascular diseases","prospective registry","international collaboration","social determinants of health","health care disparities","real world data","cardiology-oncology team work","2026-05-07",{"date":93,"type":94},"2026-05-12","ACTUAL",{"date":96,"type":94},"2022-07-01",{"date":98,"type":72},"2029-07-01",{"name":5,"class":6},1]